AptaBio Therapeutics Inc (293780) - Cash Flow Conversion Efficiency

Latest as of September 2025: -0.061x

Based on the latest financial reports, AptaBio Therapeutics Inc (293780) has a cash flow conversion efficiency ratio of -0.061x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩-2.73 Billion ≈ $-1.85 Million USD) by net assets (₩44.61 Billion ≈ $30.23 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See 293780 net asset quality index to measure how much of total assets are equity-financed.

AptaBio Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2017–2024)

This chart illustrates how AptaBio Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore AptaBio Therapeutics Inc cash debt coverage ratio to assess how comfortably operating cash covers total debt obligations.

AptaBio Therapeutics Inc Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of AptaBio Therapeutics Inc ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
Agabang&Company KQ:013990	-0.022x
UOB Kay Hian Securities (Thailand) Public Company Limited BK:UOBKH	0.148x
Young Heung I& KO:012160	0.002x
Haivision Systems Inc TO:HAI	0.127x
YHN Acquisition I Limited Ordinary Shares NASDAQ:YHNA	-0.007x
Alquiber Quality SA MC:ALQ	0.715x
Compass Digital Acquisition Corp NASDAQ:CDAQ	0.037x
Alcidion Group Ltd AU:ALC	0.113x

Annual Cash Flow Conversion Efficiency for AptaBio Therapeutics Inc (2017–2024)

The table below shows the annual cash flow conversion efficiency of AptaBio Therapeutics Inc from 2017 to 2024. For the full company profile with market capitalisation and key ratios, see market value of AptaBio Therapeutics Inc.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2024-12-31	₩54.20 Billion ≈ $36.73 Million	₩-12.16 Billion ≈ $-8.24 Million	-0.224x	+2.32%
2023-12-31	₩61.36 Billion ≈ $41.59 Million	₩-14.10 Billion ≈ $-9.55 Million	-0.230x	-76.05%
2022-12-31	₩52.37 Billion ≈ $35.49 Million	₩-6.83 Billion ≈ $-4.63 Million	-0.130x	+9.57%
2021-12-31	₩61.67 Billion ≈ $41.79 Million	₩-8.90 Billion ≈ $-6.03 Million	-0.144x	-174.59%
2020-12-31	₩72.04 Billion ≈ $48.82 Million	₩-3.79 Billion ≈ $-2.57 Million	-0.053x	+34.20%
2019-12-31	₩75.16 Billion ≈ $50.93 Million	₩-6.00 Billion ≈ $-4.07 Million	-0.080x	+16.38%
2018-12-31	₩18.31 Billion ≈ $12.41 Million	₩-1.75 Billion ≈ $-1.19 Million	-0.095x	-268.19%
2017-12-31	₩-31.54 Billion ≈ $-21.37 Million	₩-1.79 Billion ≈ $-1.21 Million	0.057x	--

About AptaBio Therapeutics Inc

KQ:293780 Korea Drug Manufacturers - Specialty & Generic

Market Cap

$83.71 Million

₩123.52 Billion KRW

Market Cap Rank

#19754 Global

#976 in Korea

Share Price

₩4595.00

Change (1 day)

+5.88%

52-Week Range

₩4000.00 - ₩10420.00

All Time High

₩61500.00